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Expression and Function of the Natural Cytotoxicity
Receptor NKp46 on Circulating Malignant CD4þ
T Lymphocytes of Se´zary Syndrome Patients
Armand Bensussan1,2, Natacha Remtoula1, Simona Sivori4, Martine Bagot1,3, Alessandro Moretta4 and
Anne Marie-Cardine1,2
The natural cytotoxicity receptors NKp30, NKp44, and NKp46 were identified as activating receptors mainly
expressed by natural killer (NK) lymphocytes. In this study we show that peripheral blood malignant CD4þ
T lymphocytes from patients with Se´zary syndrome, an aggressive form of cutaneous T-cell lymphoma, express
NKp46 at their cell surface. Although NKp46 does not behave as an independent functional receptor, its
engagement provides a strong inhibiting signal on the malignant T lymphocyte CD3-induced proliferation. We
show that this inhibition is correlated with a decreased phosphorylation of the CD3z chain associated with
NKp46 and/or the TCR/CD3 complexes. Our results reveal that in addition to KIR3DL2/CD158k expression,
NKp46 could represent an additional marker on the circulating malignant T lymphocytes of Se´zary patients,
where it displays an as yet unreported function of inhibitory co-receptor able to interfere with the processes
governing their CD3-dependent proliferation.
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INTRODUCTION
Se´zary syndrome (SS) is an aggressive leukemic and
erythrodermic variant of cutaneous T-cell lymphomas char-
acterized by the presence of a clonal T-lymphocyte popula-
tion with atypical cerebriform nuclei in the skin, lymph
nodes, and peripheral blood (Willemze et al., 2005). Because
the cytomorphological characteristic of Se´zary cells was not
specific enough to allow an unequivocal detection of the
tumoral cells, the identification of a specific marker has been
a challenging issue. Besides a T-cell CD4þCD45ROþ
phenotype, Se´zary cells were shown to lack CD26 and
CD7 and to have a diminished expression of CD3 (Edelman
and Meyerson, 2000; Bernengo et al., 2001; Rappl et al.,
2001). An aberrant expression of T-plastin and of the tyrosine
kinase receptor EphA4 has also been reported (Su et al.,
2003; van Doorn et al., 2004), as well as chromo-
somal alterations or deregulated expression of oncogene or
tumor-suppressor genes (Mao et al., 2003; Vermeer et al.,
2008). However, these characteristics do not always allow
the detection of the entire tumoral cell burden for a given
patient, and are subjected to variation from one patient to
another (Klemke et al., 2008).
We identified CD158k/KIR3DL2, a member of the killer
cell immunoglobulin-like receptor (KIR) family, as a specific
cell surface marker allowing an evaluation of the circulating
tumoral burden and the follow-up of patients with SS (Bagot
et al., 2001; Poszepczynska-Guigne et al., 2004; Ortonne
et al., 2006; Bouaziz et al., 2009). Although the functional
significance of this specific expression remains to be
elucidated, it suggested that transformed Se´zary CD4þ
T cells have acquired the ability to transcribe receptor genes
whose expression was otherwise mainly restricted to natural
killer (NK) cell lineage. Recently, it has been shown that
umbilical cord blood CD8þ T cells, when stimulated with
IL-15 for a long period of time, expressed the natural
cytotoxicity receptors (NCRs) NKp30, NKp44, and to a lesser
extent NKp46. However, only NKp30 was functional, as
demonstrated by degranulation, IFN-g release, redirected
cytotoxicity, and apoptosis (Tang et al., 2008). Such
expression of NK lineage cytotoxic receptors was also
reported in diseases involving distinct cell types. In celiac
disease, intraepithelial cytotoxic T lymphocytes (CTLs),
which are constitutively exposed to high amounts of IL-15,
express NKG2D and consequently exhibit a TCR-indepen-
dent cytolytic activity upon engagement of the receptor
(Meresse et al., 2004). More recently, these intraepithelial
CTLs were also found to aberrantly express NKG2C, NKp44,
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and NKp46. The expression of these activating NK receptors
allows the CTLs to not only kill but also secrete cytokines in
an antigen-nonspecific manner, whereas their proliferation
escapes to the control of the TCR (Meresse et al., 2006).
Similarly, an increased percentage of NKG2C-positive NK
and T cells was described in cytomegalovirus (CMV)-
seropositive patients when compared with healthy indivi-
duals (Guma et al., 2004). An expression of NKG2D,
ILT2, and KIRs was further demonstrated on human CMV-
stimulated CD4þ T lymphocytes. In these virus-specific
CD4þ T cells, NKG2D functions as a costimulatory receptor
and efficiently synergizes with TCR-dependent signals that
govern proliferation and cytokine production (Saez-Borderias
et al., 2006). It has therefore been proposed that NKG2D
expression may contribute to the response of human CMV-
specific CD4þ T cells against HLA class IIþ virus-infected
cell types expressing NKG2D ligands. The detection of
NK receptor-expressing CTLs during the progression of celiac
disease or human CMV infection raises the question of
whether the appearance of these NK-like cell populations
could be linked to the microenvironment associated with
chronic infectious or inflammatory disorders.
Until now, most of the reports that described NK cell
receptor expression on T lymphocytes referred to CD8þ
cytotoxic effector lymphocytes. In this study we report the
expression and the function of the NCR family member
NKp46 on the noncytotoxic malignant CD4þ T lymphocytes
of Se´zary patients.
RESULTS
Expression of NKp46 by circulating Se´zary cells
Our previous investigations regarding the expression of KIRs
on peripheral blood mononuclear cells (PBMCs) of patients
with SS led to the characterization of KIR3DL2/CD158k
as a reliable Se´zary cell marker in most cases, and in rare
occasions to the detection of additional HLA-C-specific
KIRs at the malignant cell surface (Bagot et al., 2001;
Poszepczynska-Guigne et al., 2004; Ortonne et al., 2006;
Marie-Cardine et al., 2007). These observations prompted us
to further investigate the possible expression of the major
histocompatibility complex class I nonspecific NK cell
surface receptors NKp30, NKp44, and NKp46, which belong
to the NCR family (Moretta et al., 2001). Because our
preliminary data did not give a clear interpretation regarding
NKp30 and NKp44 expression profiles, we focused our
attention on NKp46. Flow cytometry analyses allowed the
detection of a CD158kþ population in all 17 patients with
SS (Tables 1 and 2). Thus, according to the clinical stage of
the disease, a percentage of CD4þCD158kþ cells ranging
from 7.6 to 100% of the gated CD3þ T lymphocytes were
observed. Remarkably, a clear subset of CD4þNKp46þ cells
was detected in T lymphocytes obtained from all SS patients
(Table 1, mean: 47.1%). Comparison of the percentage of
CD4þCD158kþ , CD4þNKp46þ , and CD158kþNKp46þ
cells further revealed that the malignant T-cell population
displayed a CD4þCD158kþNKp46þ phenotype. The selec-
tive expression of NKp46 by the clonal malignant T-cell
population was definitely assessed by performing quadruple
immunolabelings on PBMCs from patients for whom the
TCRVb of their tumoral clone was determined. Thus, in
patients whose all CD4þ T lymphocytes corresponded to
the malignant T-cell clone, the tumoral T-cell population
exhibited a CD4þCD158kþNKp46þ phenotype (see
Figure 1a, patient 17, and Table 2). More importantly, when
the tumoral clone only represented part of the CD4þ T-cell
population, the tumoral T-cell subset expressed CD158k
and NKp46, whereas the nonmalignant T cells were
found negative for both receptors (Figure 1b, patient 15,
and Table 2). Finally, a nonsignificant percentage of
CD4þCD158kþ and/or CD4þNKp46þ T lymphocytes were
detected among the PBMCs isolated from patients with
mycosis fungoides (n¼5) or presenting an inflammatory
erythroderma (n¼ 10) or from healthy individuals (n¼ 4)
(mean o1%, see Table 1). Additionally, immunolabelings
performed on blood samples obtained from patients for
whom a clinical follow-up over a 2- to 3-year period was
available (4 out of 17) demonstrated that the percentage of
CD4þCD158kþNKp46þ T cells reflected the clinical course
of the disease (Table 3). Thus, remission or post-treatment
periods (after alemtuzumab administration) were associated
with the detection of low or decreased numbers of
CD4þCD158kþNKp46þ cells, respectively, whereas flares
were correlated with the highest percentage of positive cells.
Altogether, these results demonstrate that NKp46 expression
was specific to tumoral cells of Se´zary patients and might
represent a useful marker for the follow-up of the disease.
Although the expression of NCRs was shown to be
unaffected in NK cells upon addition of cytokines (Moretta
et al., 2001), the expression of numerous T-lymphocyte
receptors was reported to be induced or increased under
stimulating conditions. Flow cytometry analyses were there-
fore performed on patient cells that were exposed overnight
to a mixture of IL-2 and IL-7. Under these culture conditions,
no significant modification in the overall CD4þCD158kþ
NKp46þ T-lymphocyte percentage was observed for all
Se´zary patients (Table 1). Similarly, no IL-induced expression
of NKp46 was seen on CD4þ T cells of healthy donors and
mycosis fungoides or inflammatory erythroderma patients
(Table 1).
To ascertain the expression of NKp46 by Se´zary cells, total
RNA were prepared from sorted CD4þ T lymphocytes of SS
patients or healthy individuals and used in reverse transcrip-
tase-PCR experiments. As shown in Figure 2a, the presence of
NKp46 mRNA was demonstrated in CD4þ T cells isolated
from SS patients 3, 8, 11, and 12, but not in the one obtained
from healthy blood donors. Double-strand sequencing further
confirmed that the amplified product corresponded to NKp46
complementary DNA (data not shown). Note that the level of
detected NKp46 mRNA was proportional to the percentage
of CD4þNKp46þ circulating cells. The expression of the
NCR was further confirmed by anti-NKp46 immunoblotting
performed on NKp46 immunoprecipitates prepared from
cellular lysates of an in vitro generated Se´zary cell line or
patient sorted CD4þ T cells (Figure 2b). Thus, a specific and
effective detection of NKp46 in both the Se´zary cell line
and circulating malignant cells from the representative
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patient 3 was observed, to an amount equivalent to the one
obtained in a control NK cell line (Figure 2b). Altogether,
these data established that NKp46 is efficiently expressed in
Se´zary cells and might represent a new reliable marker of the
circulating malignant cells.
NKp46 triggering inhibits the CD3-mediated proliferation of
Se´zary cells
To further establish if NKp46 exerts any function in Se´zary
cells, its influence on the tumoral T-lymphocyte proliferation
was evaluated (Figure 3). We first observed that NKp46
Table 1. Expression of CD158k and NKp46 by CD4+ T lymphocytes of Se´zary patients
% CD4+CD158k+ % CD4+NKp46+ % CD158k+NKp46+
Patient no. Medium1 +IL-2+IL-71 Medium +IL-2+IL-7 Medium +IL-2+IL-7
1 SS 38.6 44.3 8.1 37.1 8.4 26.6
2 SS 100 100 100 100 100 100
3 SS 91.2 80.3 90.5 90.8 94.1 86.7
4 SS 16.3 15.4 15.7 13.1 11.2 11.9
5 SS 9.8 9.1 9.9 11.2 10.6 9.1
6 SS 65.5 71.8 44.3 94.7 44.6 59.6
7 SS 7.6 8.6 5.6 6.5 4.9 4.5
8 SS 100 100 100 100 100 100
9 SS 15.6 15.8 15.9 21.3 17.1 21.3
10 SS 9.2 11.2 8.6 10.6 7.8 9.6
11 SS 100 100 100 100 100 100
12 SS 12.8 15.8 13.3 14.5 5.1 14.5
13 SS 98.3 98.6 100 100 100 100
Mean 51.1 51.6 47.1 53.8 46.4 49.5
18 MF 1.5 1.2 1.5 1.4 1.8 1.7
19 MF 0.5 0.9 1.4 1.3 1.5 1.3
20 MF 0.6 0.4 0.7 0.3 1.1 0.4
21 MF 0.5 1.3 0.3 0.8 1.1 0.9
22 MF 0.9 1.0 0.3 0.8 1.1 0.9
Mean 0.8 0.9 0.8 0.9 1.3 1.0
23 IE 0.8 0.6 0.6 0.6 0.8 0.8
24 IE 0.1 0.4 0.9 0.4 1.2 1.0
25 IE 0.2 0.5 0.3 0.7 0.7 1.0
26 IE 0.4 1.1 0.7 0.9 1.1 1.1
27 IE 0.9 1.2 1.2 1.3 0.2 0.3
28 IE 0.2 1.0 0.1 0.2 1.3 1.1
29 IE 0.3 0.1 0.1 0.2 0.1 0.1
30 IE 0.6 1.3 0.5 0.3 0.7 1.1
31 IE 0.2 0.9 0.1 0.9 0.4 0.8
32 IE 0.4 0.5 1.4 1.3 0.3 1.2
Mean 0.8 0.8 0.6 0.7 0.7 0.8
Healthy A — o0.2 ND o0.2 o0.2 ND ND
Healthy B — o0.2 ND o0.2 o0.2 ND ND
Healthy C — o0.2 ND o0.2 o0.2 ND ND
Healthy D — o0.2 ND o0.2 o0.2 ND ND
Mean o0.2 ND o0.2 o0.2 ND ND
Abbreviations: IE, inflammatory erythroderma; MF, mycosis fungoides; ND, not determined; PBMC, peripheral blood mononuclear cell; SS, Se´zary syndrome.
1Freshly isolated PBMCs of healthy donors or patients diagnosed for SS, MF, or IE were left untreated or maintained overnight in culture medium supplemented
with IL-2 plus IL-7 as described in Patients and Methods.
Percent (%) corresponds to positive cells within the gated CD3+ population.
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engagement on a Se´zary cell line (Figure 3a) or PBMCs of SS
patients (Figure 3b and c, patients 3 and 6) was not sufficient
by itself to induce any change in the cell growth rate, with
their proliferation level remaining to basal level. Strikingly,
the co-ligation of CD3 and NKp46 led to a substantial
reduction or even to a complete abrogation of the
CD3-mediated proliferation of the Pno cell line or PBMCs
of patients (Figure 3a–c). Moreover, no cell death was
detected during the time course of the proliferation assay
(data not shown), arguing against the possibility of an NKp46
mAb-related toxicity. In addition, no modification in the
CD3-induced proliferation of PBMCs isolated from healthy
individuals was detected upon addition of the anti-NKp46
mAb, as exemplified with healthy donor A (Figure 3d),
demonstrating that the observed inhibition of the CD3-
mediated proliferation did not result from a general non-
specific effect on the CD4þ T cells but was restricted to the
malignant Se´zary cells. Thus, although NKp46 engagement
on Se´zary cells did not allow the generation of a TCR-
independent cell proliferation, it strongly affected the regular
activating signals resulting from CD3 triggering and govern-
ing the process of T-lymphocyte proliferation.
Mechanism of CD3-dependent signaling inhibition by NKp46
In an attempt to identify the molecular interactions involved in
the delivery of NKp46-dependent inhibition signals, the
association of the CD3 complex and/or NKp46 receptor with
the CD3z chains was investigated. Indeed, numerous studies
Table 2. Selective expression of NKp46 by malignant
clone of Se´zary patients
% Vb+CD4+ % Vb+CD158k+ % Vb+NKp46+
Patient 14 (Vb17) 99.5 98.4 98.5
Patient 15 (Vb8) 14.8 17.8 14.2
Patient 16 (Vb2) 100 100 99.5
Patient 17 (Vb2) 100 96.6 87.8
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Figure 1. Flow cytometry analysis of Se´zary syndrome tumoral cells. Peripheral blood mononuclear cells (PBMCs) from (a) patient 17 and (b) patient 15
were evaluated for TCRVb, CD4, CD158k, and NKp46 expression by immunofluorescence staining. Full histograms correspond to staining with isotypic control
mAb. Shown are the histograms and/or dot plots of gated CD4þ T cells.
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established the critical role of this transmembrane component in
the delivery of activating signals initiated both at the level of the
TCR/CD3 complexes in T lymphocytes and of NKp46 in NK
cells (Pessino et al., 1998). Immunoprecipitation experiments, in
which only the fraction of the membrane-bound receptors
recognized by the antibodies during the activation step was
recovered, were performed and first revealed using an anti-
phospho-CD3z mAb. Crosslinking of CD3 at the Se´zary cell
surface resulted in the efficient phosphorylation of the CD3z
chains that were found co-precipitated with the targeted
receptor (Figure 4, upper panel). In contrast, NKp46 triggering
did not lead to the detection of coassociated phospho-CD3z,
sustaining our previous observation that NKp46 engagement
alone did not elicit activating signals in Se´zary cells (see
Figure 3). More importantly, we observed that the simultaneous
engagement of CD3 and NKp46 also led to the detection of
receptor-associated phospho-CD3z, but to a level much lower
than the one obtained following CD3 triggering alone.
Reprobing of the blot with an anti-CD3z mAb allowed the
detection of the z chains associated with the TCR/CD3
complexes in resting cells, and of the fraction of the receptor
subunit that underwent phosphorylation upon CD3 ligation
(Figure 4, middle panel). In addition, a significant amount of z
chains was efficiently co-precipitated with NKp46 in Se´zary
cells, excluding the hypothesis that a lack of association with
the z chain adaptor molecule might be responsible for the lack
of NKp46-dependent signaling. The decreased phosphorylation
of CD3z following the co-ligation of NKp46 with CD3 was
confirmed by the lower intensity of signal that corresponded to
the phosphorylated form of the protein when compared with the
one obtained upon CD3 activation alone. Finally, when using
an anti-CD3e mAb for revelation, equal amounts of TCR/CD3
complexes were detected in the immunoprecipitates obtained
following CD3 engagement alone or in association with
NKp46, excluding the differences seen in the CD3z phosphor-
ylation status and association derived from a less efficient CD3
targeting in the presence of anti-NKp46 mAb (Figure 4, lower
panel). Altogether, these data suggested that NKp46 targeting
interferes with the accurate CD3-mediated phosphorylation of
the z chains, thus disturbing the delivery of activation signals.
DISCUSSION
In a previous report we described the presence of HLA-C-
specific activating KIRs on the malignant circulating T cells of
a unique Se´zary patient. As observed in KIR-expressing
CD4þ T lymphocytes from healthy individuals (van Bergen
Table 3. Percentage of circulating CD4+CD158k+NKp46+ cells during the course of Se´zary syndrome
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7
Patient A 3.9 56.51 0.5 90.5 100 100 —2
Patient B 0.3 19.21 9.8 0.2 8.7 4.2 —
Patient C 7.9 2.3 69.21 0.5 12.7 16.5 45.1
Patient D 7.5 3.0 1.8 15.6 60.11 — —
Blood samples were collected each 3–6 months over a period of 2 to 3 years.
1Flare followed by administration of anti-CD52 mAb alemtuzumab.
2Patient death.
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Figure 2. Expression of NKp46 by Se´zary syndrome (SS) cells. (a) Reverse
transcriptase PCR (RT-PCR) was performed on sorted CD4þ T cells from
patients 3, 8, 11, and 12 (see Table 1) (left panel) or healthy blood donors
(right panel) using primers specific for NKp46 or b-actin. Total RNA extracted
from purified peripheral blood natural killer (NK) cells of a healthy individual
was used as positive control. (b) Immunoprecipitates were prepared on
cellular lysates of Pno Se´zary cell line, SS patient sorted CD4þ T
lymphocytes, or the NKp46þ NK cell line SNK6 using an anti-CD8 or -NKp46
mAb. After separation by reducing SDS-PAGE and transfer onto
nitrocellulose, the precipitated proteins were revealed using an anti-NKp46
mAb followed by horseradish peroxidase (HRP)-coupled secondary
antibodies and an enhanced chemiluminescence (ECL) detection system. The
arrow indicates the position of NKp46 receptor.
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et al., 2004; Remtoula et al., 2008), these activating KIRs
display a DAP-12 independent co-receptor function and
upregulate the TCR-dependent proliferation and activation of
the Se´zary syndrome cells (Marie-Cardine et al., 2007),
suggesting that expression of activating NK lymphocyte
receptors can contribute to the clonal outgrowth of the
malignant CD4þ T-cell population in a minority of patients.
In this report, we demonstrate that the circulating pool of
CD4þ malignant T lymphocytes of Se´zary syndrome patients
express the activating NCR NKp46 that is not detected in
normal circulating CD4þ T cells. Surprisingly, whereas NKp46
engagement alone does not induce CD3z tyrosine phosphor-
ylation, it inhibits the CD3-mediated activation process of these
cells. NKp46 was originally identified as a specific marker for
NK cells regardless of their activation status (Sivori et al., 1997).
Our data therefore provide the first evidence of the presence of
a NCR on human noncytotoxic CD4þ T lymphocytes. Until
now, NCR expression has only been reported on cytotoxic
effector CD8þ T lymphocytes during some chronic infectious
or inflammatory diseases. This expression is specific to
malignant CD4þ T cells of SS patients and parallels the one
of KIR3DL2/CD158k (Figure 1 and Tables 1 and 2). In all cases,
NKp46 was detected at the surface of the malignant cells in the
absence of external stimulus. In addition, no NKp46-expressing
CD4þ T cells were detected in samples obtained from patients
with mycosis fongoides or exhibiting inflammatory erythroder-
ma (Table 1), suggesting that NKp46 might represent a new
diagnosis marker for Se´zary syndrome.
In NK cells, NKp46 acts as a full receptor and its engagement
triggers their natural cytotoxicity against target cells. In CD4þ T
cells from patients with acute coronary syndrome, activating
KIRs were shown to display an activating function indepen-
dently of the TCR/CD3 commitment, when coexpressed with
their dedicated adaptor protein DAP-12 (Nakajima et al., 2003).
Similarly, the expression of NK receptors by CTLs of celiac
patients resulted in cells that are able to kill and to secrete
cytokines in an antigen-nonspecific manner (Meresse et al.,
2004, 2006). In both cases, the involvement of the expressed
NK receptors in the clonal expansion of inflammatory T-cell
clones was suggested. Here, we observed that NKp46 targeting
is not sufficient by itself to initiate a signaling cascade leading to
initial activating events or cell proliferation despite its associa-
tion with the z chains. Furthermore, the CD3 complex was also
found to properly interact with the z chains, the latter
undergoing tyrosine phosphorylation upon CD3 crosslinking
in tumoral T lymphocytes of SS patients. A downregulation of
the CD3z chain expression and impairment of T-cell function
have been reported in T cells isolated from patients with various
solid and nonsolid tumors (Baniyash, 2004). The most
pronounced and reproducible observation was the total or
partial loss of z chain expression that correlated with impaired
T-cell function in vitro. Accordingly, a diminished TCR/CD3
expression was described in T cells from SS patients (Edelman
and Meyerson, 2000). However, our previous studies showed
that a CD3-mediated cell proliferation and c-Jun N-terminal
kinase-dependent pathway activation can be efficiently gener-
ated in these cells (Marie-Cardine et al., 2007). Our results now
suggested that, when brought to close proximity of the TCR/
CD3, NKp46 prevents the phosphorylation of the CD3z chain,
resulting in an overall inhibition of the CD3-mediated
activation pathway. NCR-mediated cellular inhibition has been
reported in some cell types. Thus, binding of the human CMV
protein pp65 to NKp30 on NK cells was shown to cause the
dissociation of the CD3z chain from the receptor, thus reducing
NKp30-mediating killing (Arnon et al., 2005). Similarly, when
expressed on IFN-producing cells, NKp44 was found to
mediate a reduction of IFN-a production upon exposure of
the cells to cytosine-phosphate-guanosine oligonucleotides
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Figure 3. Co-engagement of NKp46 inhibits the CD3-induced proliferation of Se´zary cells. (a) Pno Se´zary cell line, (b, c) peripheral blood mononuclear cells
(PBMCs) of Se´zary syndrome (SS) patients or (d) healthy blood donor were incubated in the presence of increasing concentrations of anti-CD3 mAb plus mIgG1
or -NKp46 mAb (1mgml–1). Where necessary, mIgG1 was also used as an isotypic control in place of the anti-CD3 mAb. 3H-thymidine incorporation was monitored
using a scintillation counter and is expressed as mean of triplicates±s.d. The results shown are representative of four independent experiments.
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(Fuchs et al., 2005). In both cases, the molecular interactions
underlying these inhibitory effects are unknown. Regarding
NKp46 engagement on Se´zary cells, we did not evidence the
recruitment of cytoplasmic protein tyrosine phosphatase, such
as SHP-1 or SHP-2, toward the receptor complexes (data not
shown), but cannot exclude the involvement of other inhibitory
mediators. In conclusion, in this study we demonstrated that
NKp46 is specifically expressed by malignant Se´zary cells
where it exhibits an as yet not reported function of inhibitory
co-receptor able to interfere with the processes governing
their CD3-dependent proliferation. Given our current data, it
remains to determine whether the negative function mediated
by NKp46 on the TCR signaling of malignant Se´zary cells
could be involved in the pathophysiology of cutaneous T-cell
lymphomas.
PATIENTS AND METHODS
Patients and cells
A total of 17 SS patients were included in this study. For all
patients, a diagnosis of SS was established based on clinical,
histological, and biological criteria. Blood from healthy
volunteers (n¼4) and patients with mycosis fungoides (n¼ 5)
or inflammatory erythroderma (n¼ 10) was also collected. All
participants gave their written informed consent. This study was
approved by the institutional ethics committee (CCPPRB,
Hopital Henri Mondor, Cre´teil, France) and was conducted
according to the Declaration of Helsinki Principles. PBMCs
were isolated by density gradient and CD4þ T lymphocytes
further obtained by magnetic-activated cell sorting (MACS)
using anti-CD4-coupled beads according to the manufacturer’s
instructions (Miltenyi Biotec, Paris, France). NK cells were
extracted from PBMCs by negative selection using a NK cell
isolation kit (Miltenyi Biotec). The Se´zary cell line Pno was
generated in vitro as described previously (Poszepczynska-
Guigne et al., 2004), and maintained in RPMI-1640 medium
supplemented with 10% human serum (Institute of Biotechnol-
ogies, Lyon, France), glutamine, penicillin, streptomycin, IL-2
(200Uml–1; a gift from Sanofi-Avantis, Labe`ge, France), and IL-
7 (5ngml–1; Peprotech, Neuilly-sur-Seine, France). Where
indicated, PBMCs of SS patients were cultured overnight in
the same conditions. The NK cell line SNK6 was grown in
RPMI-1640 medium plus 10% FCS and IL-2.
Fluorescence-activated cell sorting analysis
Quadruple immunolabelings were performed using anti-
KIR3DL2/CD158k mAb (AZ158, IgG2a; kindly provided by
Innate-Pharma, Marseille, France) plus goat anti-mouse
IgG2a secondary antibodies, anti-TcRVb, -NKp46, CD3,
and/or -CD4 mAbs (Beckman Coulter, Villepinte, France).
The corresponding control isotypic mAbs were used as
negative controls. Analyses were realized using a FC500
cytometer (Beckman Coulter).
Reverse transcriptase-PCR
Total RNAs were extracted using Trizol (Invitrogen, Cergy-
Pontoise, France) and subjected to reverse transcription as
previously described (Giustiniani et al., 2009). Complemen-
tary DNA amplification was done according to standard
procedures with specific primers for NKp46 (forward: 50-
GATCTCGGGAGAGAAGGTGACCTTC-30, reverse: 50-TCA
AAGAGTCTGTGTGTTCAGCCTTC-30) leading to a product
of 522 bp. Amplification of b-actin was performed as internal
control. PCR products were separated on a 1% agarose gel.
Cell activation, immunoprecipitation, and immunoblotting
Cells were incubated with 1mgml–1 of anti-CD3 (CD3x3, IgG1;
produced locally) or NKp46 mAb (clone 195314; R&D
Systems, Lille, France) alone or in combination for 5minutes
at room temperature. When necessary, anti-CD16 mAb was
used to normalize the amount of antibodies added to the cells.
Cell activation was conducted by addition of goat anti-mouse
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Figure 4. NKp46 ligation on Se´zary syndrome cells hinders the
phosphorylation of the f chains. Freshly isolated Se´zary syndrome cells were
incubated with anti-CD3 and/or -NKp46 mAbs, as indicated. An isotype matched
control mAb (anti-CD16) was used to equalize the amount of antibodies used in
each condition. Crosslinking was induced by addition of goat anti-mouse Igs
(þCL) except for resting condition (CL). After lysis, the antibody-targeted
molecules were collected and the resulting immunoprecipitates subjected to
nonreducing electrophoresis and western blotting procedures. The immunoblot
was revealed with an anti-phospho-CD3z mAb (upper panel), and reprobed in
series after dehybridization using an anti-CD3z (middle panel) or -CD3e (lower
panel) mAb. Shown are results representative of three independent experiments.
The upper and lower arrows indicate the position of the phosphorylated and
nonphosphorylated CD3z chains, respectively.
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IgG antibodies (3mgml–1; Jackson ImmunoResearch, Beckman
Coulter) and subsequent incubation for 5minutes at 37 1C.
After washes and lysis, protein G Sepharose beads were
directly added to postnuclear supernatants in order to
precipitate the receptors targeted during the activation step.
For NKp46 immunoprecipitation, anti-NKp46 mAb was
added to cellular lysates and incubation conducted for 1 hour
at 4 1C. Anti-CD8 mAb (Beckman Coulter) was used as
isotypic control mAb. Immunoprecipitates were subsequently
collected with protein G Sepharose beads.
Immune complexes were separated by SDS-8% PAGE
under reducing or nonreducing conditions, as indicated.
Proteins were electrotransferred onto a nitrocellulose mem-
brane and subjected to immunoblotting with anti-phospho-
CD3z, -CD3z, -NKp46 (all from Tebu-Bio, Le Perray en
Yvelines, France), or -CD3e (Millipore, Molsheim, France)
mAbs. Revelation was realized with the appropriated horse-
radish peroxidase-conjugated secondary antibodies and an
enhanced chemiluminescence detection system, according
to the manufacturer’s recommendations.
Proliferation assays
Round-bottomed 96-well culture plates were precoated with
suboptimal to optimal concentrations of anti-CD3 mAb in
combination with 0.5 mg per well of mIgG1 (Beckman-
Coulter) used as isotype matched negative control or anti-
NKp46 mAb. After washes, cells (75 103 per well) were
added and assays were conducted as previously described
(Poszepczynska et al., 2000). Results were expressed as the
mean of triplicates SD.
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